Literature DB >> 3496391

C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes.

N Haeffner-Cavaillon, J M Cavaillon, M Laude, M D Kazatchkine.   

Abstract

Purified human C3a(C3adesArg) induced dose-dependent generation of intracellular IL 1 activity and release of IL 1 in cultures of human mononuclear adherent cells in serum-free conditions. Concentrations of C3a(C3adesArg) of 10(-8) M and 6 hr of culture were sufficient to induce production of cell-associated IL 1, as detected in monocyte lysates. Ten- to 100-fold higher concentrations of C3a(C3adesArg) and 24 hr of culture were required for induction of IL 1 release. Release of IL 1 induced by suboptimal amounts of C3a(C3adesArg) was greatly enhanced by the addition of indomethacin to the culture medium. Contamination with C5a of the C3a(C3adesArg) preparation did not account for C3a(C3adesArg)-induced IL 1 production. Induction of IL 1 activity by C3a(C3adesArg) was not due to contaminating LPS, as indicated by the following observations: the amount of contaminating LPS in C3a(C3adesArg) was below that which could induce IL 1 release from human monocytes in serum-free conditions; induction of IL 1 by C3a(C3adesArg) was not suppressed by polymyxin B; kinetics of IL 1 production and release in the presence of C3a(C3adesArg) differed from those observed in the presence of LPS; and sialated gangliosides, which inhibit IL 1 release induced by LPS, had no effect on the induction of IL 1 by C3a(C3adesArg). The C3a(C3adesArg) preparation used in this study mostly contained the desArg derivative, suggesting that, in contrast with the requirement for an intact C-terminal arginyl residue for the spasmogenic activity of C3a, both C3a and its C3adesArg derivative may interact with receptors on human monocytes. By inducing IL 1 production and release, C3a(C3adesArg) may contribute to the generation of the inflammatory process and the regulation of the immune response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496391

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  Complementing the inflammasome.

Authors:  Martha Triantafilou; Timothy R Hughes; Bryan Paul Morgan; Kathy Triantafilou
Journal:  Immunology       Date:  2016-02       Impact factor: 7.397

2.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome.

Authors:  S Stöve; T Welte; T O Wagner; A Kola; A Klos; W Bautsch; J Köhl
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

3.  Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure.

Authors:  A K Cheung; C J Parker; L Wilcox
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 4.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

5.  Evidence for in vivo degradation of C3a anaphylatoxin by mast cell chymase. I. Nonspecific activation of rat peritoneal mast cells by C3ades Arg.

Authors:  T Kajita; T E Hugli
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

6.  Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies.

Authors:  J Zwirner; O Götze; G Begemann; A Kapp; K Kirchhoff; T Werfel
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

7.  Characterization of C3a anaphylatoxin receptor on guinea-pig macrophages.

Authors:  Y Murakami; T Imamichi; S Nagasawa
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

8.  Fc receptor function and circulating immune complexes in gluten sensitive enteropathy--possible significance of serum IgA.

Authors:  B Lavö; B Nilsson; L Lööf; U R Nilsson; K N Ekdahl
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

9.  The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1.

Authors:  H Montz; K C Koch; R Zierz; O Götze
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

Review 10.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.